ReviewAdvances in therapy2026
Exploration of Real-World Data Sources in Latin America, Middle East and North Africa, and Asia Pacific, to Support Oncology Evidence Generation: A Targeted Literature Review and Regional Recommendations.
Review in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn recent years, the role and utility of real-world evidence in complementing randomized controlled trials in oncology has become increasingly evident, accompanied by ongoing progress in real-world data (RWD) capabilities. Beyond Western regions such as North America and Europe, RWD in the broader international landscape has similarly matured, but is comparatively not as well characterized.
methodsRecognizing a need to better understand contemporary availability and characteristics of oncology RWD sources outside North America and Europe, a targeted literature review was conducted, focused on English language articles published from January 1, 2020 to May 1, 2025. The review encompassed select representative countries from Latin America (LATAM), Middle East and North Africa (MENA), and Asia Pacific (APAC).
resultsOf the 466 publications ultimately included in review, data extraction yielded 103 unique oncology RWD sources (61 in LATAM, 9 in MENA, 33 in APAC). Across the regions, similarities and differences were observed. While some countries like Brazil and Taiwan demonstrate potential impact of government-led initiatives across the entire health system, other countries like Argentina and Mexico rely more on site-level or network/consortium approaches for data collection and analysis. Overall, a common trend was seen in emerging examples of progress towards advanced RWD capabilities such as biobanks or clinicogenomic datasets.
conclusionLooking ahead, continued investment and coordinated, multi-stakeholder effort will be critical to fully realize potential of oncology RWD in these regions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.